(MedPage Today) — PHILADELPHIA — Most multi-food allergic children succeeded in longer term regular dietary consumption whether treated with oral immunotherapy (OIT) or omalizumab (Xolair) alone, results from stage 3 of the OUtMATCH trial showed…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
